Free Trial
NASDAQ:CALA

Calithera Biosciences (CALA) Stock Price, News & Analysis

Calithera Biosciences logo
$0.0020 0.00 (-47.37%)
As of 06/3/2025 02:56 PM Eastern

About Calithera Biosciences Stock (NASDAQ:CALA)

Key Stats

Today's Range
$0.0002
$0.0020
50-Day Range
N/A
52-Week Range
$0.00
$0.05
Volume
891 shs
Average Volume
16,732 shs
Market Capitalization
$9,740.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Stock News Headlines

Calithera Biosciences Inc (CALA)
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Arcus Biosciences Inc (RCUS)
Christina Cala
CALA - Calithera Biosciences, Inc.
See More Headlines

CALA Stock Analysis - Frequently Asked Questions

Calithera Biosciences' stock was trading at $0.0001 at the beginning of 2025. Since then, CALA stock has increased by 1,900.0% and is now trading at $0.0020.
View the best growth stocks for 2025 here
.

Calithera Biosciences, Inc. (NASDAQ:CALA) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter.

Calithera Biosciences shares reverse split on the morning of Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR).

Company Calendar

Last Earnings
11/08/2021
Today
6/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
60
Year Founded
2010

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
4,550,000
Market Cap
$9,740.00
Optionable
Not Optionable
Beta
-2.38

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CALA) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners